Collaborations

The company has collaboration agreements with the Foundation for Biomedical Research at the Puerta de Hierro University Hospital (Madrid, Spain) focused on conducting immunogenicity, pharmacokinetics and biodistribution studies in mice; the Centre for Applied Medical Research (CIMA, Pamplona, Spain) to address the in vivo efficacy of Trimerbody-based molecules in experimental models of cancer; and the Research Biomedicine Institute Alberto Sols (IIBm, Madrid, Spain) to assess the intracellular signaling events induced by specific candidate molecules. In addition, the company is collaborating with the Spanish National Cancer Research Center (CNIO, Madrid, Spain) to address the structures of the Trimerbody-based molecules.

Latest News

Clave Capital invests in Leadartis in a funding round of more than €1,600,000
14-05-2021

Clave Capital, through the fund Navarra Tech Transfer, consolidates with this new operation its...

Sodena and Capital Cell invest €1.600.000 in the biopharmaceutical Leadartis
30-04-2021

The entry of funds into leadartis' shareholding is part of a round of financing closed by...

Leadartis announces the publication "An Fc-free EGFR-specific 4-1BB-agonistic trimerbody displays broad anti-tumor activity in humanized murine cancer models without toxicity” in Clinical Cancer Research
02-04-2021